肝动脉灌注化疗联合仑伐替尼治疗巴塞罗那临床肝癌B或C期肝细胞癌

目的 观察肝动脉灌注化疗（HAIC）联合仑伐替尼治疗巴塞罗那临床肝癌（BCLC）B或C期肝细胞癌（HCC）效果，分析影响患者生存时间的因素。方法 回顾性分析104例BCLC B或C期HCC患者资料，根据治疗方案将其归入观察组（46例，接受HAIC联合仑伐替尼治疗）及对照组（58例，仅接受HAIC）；比较2组疗效、不良反应及患者总生存期（OS）和无进展生存期（PFS），以Cox回归分析评估OS影响因素。结果 治疗后3、6个月，观察组改良实体瘤疗效评价标准（mRECIST）评估结果均优于对照组（P均＜0.05）；治疗后1年，组间mRECIST评估结果差异无统计学意义（P＞0.05）。观察组患者总生存率高于对照组（P＜0.05），而组间无进展生存率差异无统计学意义（P＞0.05）。观察组皮疹发生率高于对照组（P＜0.05）。多因素Cox回归分析结果显示，相比单一HAIC，HAIC联合仑伐替尼［风险比（HR）=0.425，95%CI（0.255，0.791）］可延长患者OS；相比治疗前美国东部肿瘤协作组（ECOG）评分 1、AFP≥400 μg/ml、瘤灶数目≥3及BCLC C期，治疗前ECOG评分 0、AFP＜400 μg/ml、瘤灶数目≤2及BCLC B期均为HCC患者OS独立保护因素（P均＜0.05）。结论 HAIC联合仑伐替尼治疗BCLC B期或C期HCC安全、有效；治疗前ECOG评分、血清AFP水平、瘤灶数目及BCLC分期均为OS影响因素。

Hepatic artery infusion chemotherapy combined with lenvatinib for treating Barcelona clinic liver cancer stage B or C hepatocellular carcinoma

Objective To observe the efficacy of hepatic artery infusion chemotherapy （HAIC） combined with lenvatinib for treating Barcelona clinic liver cancer （BCLC） stage B or C hepatocellular carcinoma （HCC）， and to explore the impact factors of patients’ survival time. Methods Data of 104 patients with BCLC stage B or C HCC were retrospectively analyzed. The patients were divided into observation group （n=46， underwent HAIC combined with lenvatinib）and control group （n=58， underwent HAIC alone）. The clinical efficacy and adverse reactions of treatments， as well as patients’ overall survival （OS） and progression free survival （PFS） were recorded and compared between groups. Cox regressions were used to explore the impact factors of patients’ survival time. Results Three months and 6 months after HAIC， the results of modified response evaluation criteria in solid tumors （mRECIST） in observation group were both better than those in control group （both P＜0.05）， while no significant difference was found between groups one year after HAIC （P＞0.05）. The overall survival rate in observation group was higher than that in control group （P＜0.05）， while there was no significant difference of progression free survival rate between groups （P＞0.05）. The incidence of rash in observation group was higher than that in control group （P＜0.05）. Multiple Cox regression showed prolonged OS in HCC patients in observation group （hazard ratio ［HR］=0.425， 95%CI ［0.255， 0.791］） compared with that in control group. Compared with pre-treatment Eastern Cooperative Oncology Group （ECOG） score 1， AFP≥400 μg/ml， the number of tumor foci≥3 and BCLC stage C， pre-treatment ECOG score 0， AFP＜400 μg/ml， the number of tumor foci≤2 and BCLC stage B were all independent protective factors of OS in HCC patients （all P＜0.05）. Conclusion HAIC combined with lenvatinib was safe and effective for treating BCLC stage B or C HCC. Pre-treatment ECOG score， serum AFP level， the number of tumor foci and BCLC stage were all independent impact factors of OS.